Literature DB >> 7539523

Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies.

D M Jackson1, N Mohell, J Georgiev, A Bengtsson, L G Larsson, O Magnusson, S B Ross.   

Abstract

The aim of the present study was to further investigate the behavioural and biochemical pharmacology of the directly acting dopamine (DA) receptor agonist bromocriptine (BRC). BRC produced an initial depression of locomotion followed after about an hour by a weak but significant locomotor stimulation. The stimulation was potentiated by concomitant administration of the D1 agonist SKF38393. Ex vivo biochemical determinations indicated that reductions in dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels occurred in the striatum after BRC injection without a significant change in DA levels, indicating a reduced DA turnover. An increase in 5-hydroxytryptamine (5HT) and 5-hydroxyindoleacetic acid (5HIAA) levels occurred in the striatum leading to a significant increase in turnover (i.e. ratio of 5HIAA to 5HT). Noradrenaline concentrations increased in the striatum. In the cortex, sharp falls in HVA and DOPAC levels without a corresponding change in DA were observed. While there was no significant change in noradrenaline levels in this brain region, an increase in 5HIAA, but not in 5HT, levels occurred. These changes indicate an increase in 5HT turnover (ratio of 5HIAA to 5HT). In vivo dialysis indicated that extracellular levels of DA, DOPAC and HVA in the striata of freely moving rats were sharply reduced for at least 6 h after injection. In vitro binding studies showed that BRC exhibited high (Ki values in low nanomolar range) affinities for DA D2A, D2B, D3, alpha 1 and alpha 2 adrenergic receptors together with unexpectedly high affinity (about 1 nM) for 5HT1A receptors. The data indicate that the initial behavioural depression and later locomotor stimulation induced by BRC are accompanied by a sharp monophasic fall in striatal extracellular DA levels as indicated by dialysis studies. Since the behavioural stimulation was augmented by concomitant D1 receptor stimulation, the data suggest that the reduced DA turnover is influencing the amount of DA available to stimulate postsynaptic D1 receptors. However, the biochemical studies indicated that BRC has a high affinity for 5HT1A receptors and affects the turnover of 5HT in the brain. Thus, the behavioural effects of BRC may depend not only on effects on the DA system but also on 5HT systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539523     DOI: 10.1007/bf00169328

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  44 in total

Review 1.  5-HT receptors: subtypes and second messengers.

Authors:  D Hoyer; P Schoeffter
Journal:  J Recept Res       Date:  1991

Review 2.  Are neostriatal dopamine receptors co-localized?

Authors:  D J Surmeier; A Reiner; M S Levine; M A Ariano
Journal:  Trends Neurosci       Date:  1993-08       Impact factor: 13.837

3.  Chronic BRL 43694, a selective 5-HT3 receptor antagonist, fails to alter the number of spontaneously active midbrain dopamine neurons.

Authors:  C R Ashby; L H Jiang; R Y Wang
Journal:  Eur J Pharmacol       Date:  1990-01-17       Impact factor: 4.432

4.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

5.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

6.  Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.

Authors:  M Goldstein; A Lieberman; A F Battista; J Y Lew; F Hata
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

7.  Photocell measurements of rat motor activity. A contribution to sensitivity and variation in behavioral observations.

Authors:  E Ericson; J Samuelsson; S Ahlenius
Journal:  J Pharmacol Methods       Date:  1991-04

Review 8.  Dopamine receptor pharmacology.

Authors:  P Seeman; H H Van Tol
Journal:  Curr Opin Neurol Neurosurg       Date:  1993-08

9.  Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.

Authors:  A Imperato; G Tanda; R Frau; G Di Chiara
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

10.  Evidence for an irreversible interaction of bromocryptine with central dopamine receptors.

Authors:  M J Bannon; A A Grace; B S Bunney; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

View more
  2 in total

1.  Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine.

Authors:  Brian C Nolan; Shinban Liu; Lindsey R Hammerslag; Timothy H C Cheung; Jeffrey Lenz; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  Synapse       Date:  2013-07-17       Impact factor: 2.562

2.  Real Time Imaging of Biomarkers in the Parkinson's Brain Using Mini-Implantable Biosensors. II. Pharmaceutical Therapy with Bromocriptine.

Authors:  Patricia A Broderick; Edwin H Kolodny
Journal:  Pharmaceuticals (Basel)       Date:  2009-12-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.